HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI

被引：18

作者：

Mok, Tony ^{[1
,2
]}

Jaenne, Pasi A. ^{[3
]}

Nishio, Makoto ^{[4
]}

Novello, Silvia ^{[5
]}

Reck, Martin ^{[6
]}

Steuer, Conor ^{[7
]}

Wu, Yi-Long ^{[8
]}

Fougeray, Ronan ^{[9
]}

Fan, Pang-Dian ^{[9
]}

Meng, Jie ^{[9
]}

Sternberg, David W. ^{[9
]}

Esker, Stephen ^{[9
]}

Yu, Helena A. ^{[10
]}

机构：

[1] State Key Lab Translat Oncol, Dept Clin Oncol, Hong Kong, Peoples R China

[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[3] Dana Farber Canc Inst, Med Oncol, Boston, MA 02215 USA

[4] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Thorac Med Oncol, Tokyo 1358550, Japan

[5] Univ Turin, San Luigi Hosp Orbassano, Oncol Dept, I-10124 Turin, Italy

[6] LungenClin, Airway Res Ctr North, German Ctr Lung Res, Dept Thorac Oncol, D-22927 Grosshansdorf, Germany

[7] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA

[8] Guangdong Prov Peoples Hosp, Lung Canc Inst, Guangzhou 510317, Peoples R China

[9] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ 07920 USA

[10] Mem Sloan Kettering Canc Ctr, Med Oncol, Dept Med, New York, NY 10065 USA

来源：

FUTURE ONCOLOGY | 2024年 / 20卷 / 15期

关键词：

antibody-drug conjugate; EGFR-activating mutation; HER3-DXd; non-small-cell lung cancer; patritumab deruxtecan; CELL LUNG-CANCER; OSIMERTINIB; INHIBITOR; GEFITINIB; CARBOPLATIN; PACLITAXEL; RESISTANCE; EFFICACY; DS-8201A;

D O I：

10.2217/fon-2023-0602

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

After disease progression on EGFR tyrosine kinase inhibitor (TKI) therapy, patients with EGFR-mutated NSCLC who are then treated with platinum-based chemotherapy (PBC) obtain only limited clinical benefit with transient responses. Therapies with greater efficacy and tolerable safety profiles are needed in this setting. The receptor tyrosine kinase HER3 is widely expressed in NSCLC, and increased expression is associated with poor treatment outcomes. In the U31402-A-U102 phase I trial, HER3-DXd showed promising antitumor activity with manageable safety in heavily pre-treated patients with EGFR-mutated NSCLC across a range of tumor HER3 expression levels and EGFR TKI resistance mechanisms. HERTHENA-Lung02 is the first phase III trial to evaluate the safety and efficacy of HER3-DXd versus PBC in patients with progression on a third-generation EGFR TKI.

引用

页码：969 / 980

页数：12

共 50 条

[31] Exploration of Acquired Resistance Mechanisms to the 4th-Generation EGFR-TKI in EGFR-Mutated Lung Cancer - An in Vitro Study
Fukuda, S.
Suda, K.
Hamada, A.
Oiki, H.
Ohara, S.
Ito, M.
Soh, J.
Mitsudomi, T.
Tsutani, Y.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S455 - S455
[32] Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study
Steendam, Christi M. J.
Ernst, Sophie M.
Badrising, Sushil K.
Paats, Marthe S.
Aerts, Joachim G. J. V.
de Langen, Adrianus J.
Dingemans, Anne-Marie C.
LUNG CANCER, 2023, 181
[33] Lazertinib, a Third Generation EGFR-TKI, in Patients with EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/II Study
Cho, B. C.
Han, J.
Kim, S.
Lee, K.
Kim, D.
Lee, Y.
Lee, G.
Lee, J.
Cho, E. K.
Kim, J.
Lee, S. S.
Min, Y. J.
Kim, J.
Shin, S. W.
Kim, H. R.
Hong, M. H.
Ahn, J. S.
Kang, S.
Kim, S.
Jang, S. B.
Choi, S.
Ahn, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S453 - S453
[34] A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure
Lam, T. C.
Tsang, K.
Choi, H.
Lee, V. H. F.
Lam, K. O.
Chiang, C. L.
So, T. H.
Chan, W. W.
Nyaw, S. F.
Lim, F.
Lau, J. O.
Chik, J.
Kong, S. F.
Lee, A. W. M.
ANNALS OF ONCOLOGY, 2020, 31 : S1389 - S1389
[35] Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases
Haoran Qi
Yichen Hou
Zhonghang Zheng
Mei Zheng
Qiang Qiao
Zihao Wang
Xiaorong Sun
Ligang Xing
BMC Cancer, 24
[36] Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases
Qi, Haoran
Hou, Yichen
Zheng, Zhonghang
Zheng, Mei
Qiao, Qiang
Wang, Zihao
Sun, Xiaorong
Xing, Ligang
BMC CANCER, 2024, 24 (01)
[37] First-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI
Husain, H.
Martins, R. G.
Goldberg, S. B.
Senico, P.
Ma, W.
Masters, J.
Pathan, N.
Kim, D-W.
Socinski, M. A.
Goldberg, Z.
Cho, B. C.
ANNALS OF ONCOLOGY, 2017, 28
[38] Phase 1/2 Clinical Trial of JIN-A02, a 4th Generation EGFR-TKI in EGFR Mutated Advanced/metastatic Non-Small Cell Lung Cancer (NSCLC)
Lim, S. M.
Cho, B. C.
Han, J. Y.
Kim, S. W.
Lee, K. H.
Nagasaka, M.
Jo, A.
Seah, E.
Kim, C.
Reungwetwattana, T.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S346 - S346
[39] Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer
Hirano, Toshiyuki
Yasuda, Hiroyuki
Hamamoto, Junko
Nukaga, Shigenari
Masuzawa, Keita
Kawada, Ichiro
Naoki, Katsuhiko
Niimi, Tatsuya
Mimasu, Shinya
Sakagami, Hideki
Soejima, Kenzo
Betsuyaku, Tomoko
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (04) : 740 - 750
[40] Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01
Johnson, M. L.
Janne, P. A.
Goto, Y.
Yoh, K.
Lee, S-H.
Paz-Ares, L.
Besse, B.
Novello, S.
Hayashi, H.
Kim, D-W.
John, T.
Kao, S. C-H.
Felip, E.
Yang, J. C-H.
Reck, M.
Dong, Q.
Sporchia, A.
Sternberg, D. W.
Yu, H. A.
ANNALS OF ONCOLOGY, 2023, 34

← 1 2 3 4 5 →